drugset / Trial / NCT00323830

Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma

NCT00323830 ↗

Phase 3 Completed 458 enrolled Samsung Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of the trial is to compare disease-free survival between adjuvant capecitabine/cisplatin alone vs capecitabine/cisplatin with radiotherapy (chemoradiation) in curatively resected gastric cancer patients.

Timeline

Start
2004-10
Primary completion
2008-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Background Capecitabine Small molecule — —
Background Cisplatin Other / unclassified — —

Indications